Cross-over-it's a feature, not a bug

Ann Oncol. 2015 Sep;26(9):2000-2002. doi: 10.1093/annonc/mdv260. Epub 2015 Jun 15.

Abstract

Pharmaceutical companies, investigators, regulators, and payers need to work together to adapt standards for drug development that meet the needs of all stakeholders, but first and foremost, benefit cancer patients in the most appropriate way.

Publication types

  • Editorial

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Crizotinib
  • Drug Discovery / methods*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / mortality
  • Molecular Targeted Therapy / methods*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / therapeutic use
  • Pyridines / therapeutic use
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases